Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer.

British Journal of Anaesthesia
Giacomo MontagnaJoshua S Mincer

Abstract

Opioid-induced immunomodulation may be of particular importance in triple-negative breast cancer (TNBC) where an immune response is associated with improved outcome and response to immunotherapy. We evaluated the association between intraoperative opioids and oncological outcomes and explored patterns of opioid receptor expression in TNBC. Consecutive patients with stage I-III primary TNBC were identified from a prospectively maintained database. Opioid receptor expression patterns in the tumour microenvironment were analysed using publicly available bulk and single-cell RNA-seq data. A total of 1143 TNBC cases were retrospectively analysed. In multivariable analysis, higher intraoperative opioid dose was associated with favourable recurrence-free survival, hazard ratio 0.93 (95% confidence interval 0.88-0.99) per 10 oral morphine milligram equivalents increase (P=0.028), but was not significantly associated with overall survival, hazard ratio 0.96 (95% confidence interval 0.89-1.02) per 10 morphine milligram equivalents increase (P=0.2). Bulk RNA-seq analysis of opioid receptors showed that OPRM1 was nearly non-expressed. Compared with normal breast tissue OGFR, OPRK1, and OPRD1 were upregulated, while TLR4 was downregulated. ...Continue Reading

References

Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P R RosenS Hellman
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A QuietS Hellman
Sep 29, 2006·Anesthesiology·Aristomenis K ExadaktylosDaniel I Sessler
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Feb 24, 2012·Anesthesiology·Frances E LennonPatrick A Singleton
Aug 7, 2013·Experimental Biology and Medicine·Ian S ZagonPatricia J McLaughlin
Jan 9, 2014·Expert Review of Anticancer Therapy·Patricia J McLaughlin, Ian S Zagon
Dec 18, 2014·Genome Biology·Michael I LoveSimon Anders
Mar 6, 2015·Critical Care Nursing Quarterly·Kristen Starnes-OttJanet C Meininger
Dec 17, 2015·Nature Reviews. Clinical Oncology·Peter SavasSherene Loi
Mar 2, 2016·Regional Anesthesia and Pain Medicine·Abraham M TsigonisJeffrey Landercasper
Mar 19, 2016·Current Opinion in Supportive and Palliative Care·Timothy Wigmore, Paul Farquhar-Smith
May 7, 2016·Science·Christian U BlankTon N Schumacher
Jun 28, 2016·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Ravi K GrandhiAlaa Abd-Elsayed
Sep 23, 2016·The New England Journal of Medicine·Robert L GrossmanLouis M Staudt
Oct 25, 2016·Regional Anesthesia and Pain Medicine·Juan P CataVijaya Gottumukkala
Jun 9, 2017·British Journal of Pharmacology·Jason W Boland, A Graham Pockley
Mar 8, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nan XieMarie-Odile Parat
Sep 6, 2018·Nature Communications·Mihriban KaraayvazLeif W Ellisen
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Oct 1, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J H ParkS Michiels
Oct 28, 2019·Lancet·Daniel I SesslerUNKNOWN Breast Cancer Recurrence Collaboration
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J H ParkS Michiels
Feb 6, 2020·Nature Methods·Pauli VirtanenUNKNOWN SciPy 1.0 Contributors
Feb 26, 2020·Current Treatment Options in Oncology·Jaya Amaram-DavilaAkhila Reddy
Feb 27, 2020·The New England Journal of Medicine·Peter SchmidUNKNOWN KEYNOTE-522 Investigators
Apr 22, 2020·Annals of Surgical Oncology·Dan MoldoveanuSarkis Meterissian

❮ Previous
Next ❯

Citations

Oct 13, 2021·Pain Management·Maria F RamirezJuan P Cata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.